Cat. No. | Product Name | Field of Application | Chemical Structure |
---|---|---|---|
DC10372 | Amcasertib(BBI503) Featured |
Amcasertib(BBI503) is an orally administered investigational agent designed to inhibit cancer stem cell pathways, including Nanog, by targeting stemness kinases.
More description
|
![]() |
DC5065 | Golvatinib (E7050) Featured |
E-7050 is hepatocyte growth factor receptors (HGFR).
More description
|
![]() |
DC10440 | Namodenoson (CF-102) Featured |
CF-102(2-Cl-IB-MECA) is a selective A3 adenosine receptor agonist (Ki = 0.33 nM). Displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively.
target: A3 adenosine receptor agonist;
More description
|
![]() |
DC11163 | AST-3424 Featured |
AST-3424 (OBI-3424, TH-3424) is a first-in-class, novel prodrug that selectively targets cancers overexpressing the enzyme AKR1C3, OBI-3424 is a highly selective prodrug that is converted by AKR1C3 to a DNA alkylating agent.
More description
|
![]() |
DC7065 | Tivantinib (ARQ 197) Featured |
Tivantinib (ARQ 197) is the first non-ATP-competitive c-Met inhibitor with Ki of 0.355 μM, little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4.
More description
|
![]() |
DC10033 | H3B-6527 Featured |
H3B-6527 is an orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity.
More description
|
![]() |
DC10128 | FGF401( Roblitinib) Featured |
FGF401 is an inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity.
More description
|
![]() |
DC10092 | BLU554(Fisogatinib) Featured |
BLU-554 is a potent fibroblast growth factor receptor 4 (FGFR4) inhibitor.
More description
|
![]() |
DC5032 | AZD1480 Featured |
AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1/2.
More description
|
![]() |
DC4105 | Linsitinib(OSI-906) Featured |
OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R and IR with IC50 of 35 nM and 75 nM, respectively.
More description
|
![]() |
DC7808 | Refametinib (BAY86-9766) Featured |
Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.
More description
|
![]() |
DC10559 | Derazantinib (ARQ 087) Featured |
Derazantinib (Derazantinib) is an ATP competitive tyrosine kinase inhibitor; exhibits potent activity against FGFR1-3 chondrocytes with IC50s of 4.5, 1.8, and 4.5 nM, respectively.
More description
|
![]() |
DC2019 | Brivanib (bms-540215) Featured |
Brivanib is an ATP-competitive inhibitor against human VEGFR2 and FGFR with IC50 of 25 nM and 148 nM, respectively.
More description
|
![]() |
DC11087 | TRX-818 sodium |
TRX-818 sodium (Foslinanib sodium ) is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities, induces cancer cell apoptosis and inhibits cancer cell proliferation.
More description
|
![]() |
DC11812 | SF-1126 |
SF-1126 is a pan PI3K/BRD4 inhibitor, RGDS-conjugated LY294002 prodrug that exhibits increased solubility and binds to specific integrins.
More description
|
![]() |
DC7261 | Resminostat hydrochloride (4SC-201) |
Resminostat(RAS2410; 4SC-201) is a potent inhibitor of HDAC1/3/6(IC50=43-72 nM); less potent to HDAC8 with IC50 of 877 nM.
More description
|
![]() |
DC11086 | Foslinanib |
Foslinanib (TRX-818) is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities, induces cancer cell apoptosis and inhibits cancer cell proliferation.
More description
|
![]() |
DCAPI1441 | Seocalcitol |
EB1089 is an analog of 1,25 dihydroxyvitamin D which acts as a vitamin D receptor (VDR). EB1089 is noted to reverse hypercalcemia and is a potent inhibitor of PTH-rP (parathyroid hormone-related peptide, PTHRP) in vitro. In studies utilizing a squamous ca
More description
|
![]() |
DC11295 | AZD-4573 |
AZD4573 is a CDK9 inhibitor with an IC50 of <3 nM extracted from patent US 20160376287 A1, example 14.
More description
|
![]() |